"10.1371_journal.pone.0118787","plos one","2015-03-05T00:00:00Z","Andrew C Harris; Mark G LeSage; David Shelley; Jennifer L Perry; Paul R Pentel; S Michael Owens","Minneapolis Medical Research Foundation, Minneapolis, Minnesota, United States of America; Department of Medicine, University of Minnesota Medical School, Minneapolis, Minnesota, United States of America; Department of Pharmacology and Toxicology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America","Conceived and designed the experiments: ACH MGL JLP PRP SMO. Performed the experiments: DS JLP. Analyzed the data: ACH MGL. Contributed reagents/materials/analysis tools: MGL PRP SMO. Wrote the paper: ACH MGL SMO.","SMO is Chief Scientific Officer of and has financial interests in InterveXion Therapeutics, LLC, a pharmaceutical biotech company, whose main interest is the development of antibody medications for the treatment of human diseases, including drug abuse. This does not alter the authorsâ€™ adherence to PLOS ONE policies on sharing data and materials.",21,2,1,"2015","03","Andrew C Harris","ACH",6,TRUE,5,2,2,3,TRUE,TRUE,FALSE,0,NA,FALSE
